TABLE 2.
Test properties for ATL forms and controls
| Sample type/test | Mucosal leishmaniasis |
Cutaneous leishmaniasis |
American tegumentary leishmaniasisa |
||||
|---|---|---|---|---|---|---|---|
| Positivity (no./total no. tested) | Sensitivity (% [95% CI]) | Positivity (no./total no. tested) | Sensitivity (% [95% CI]) | Sensitivity (% [95% CI]) | Specificity (% [95% CI]) | Accuracy (% [95% CI]) | |
| Biopsy/SYBR Green | 9/13 | 69.23 (42.37–87.32) | 22/29 | 75.86 (57.89–87.78) | 73.81 (58.93–84.70) | 100 (86.65–100) | 84.72 (74.68–91.25) |
| Biopsy/ TaqMan | 6/13 | 46.15 (23.21–70.86) | 17/29 | 58.62 (40.74–74.49) | 54.76 (39.95–68.78) | 100 (88.65–100) | 73.61 (62.42–82.41) |
| Swab/SYBR Green | 7/14 | 50 (26.80–73.20) | 17/18 | 94.44 (74.24–99.01) | 75 (57.89–86.75) | 100 (89.85–100) | 87.88 (77.86–93.73) |
| Swab/TaqMan | 6/14 | 42.86 (21.38–67.41) | 12/18 | 66.67 (43.75–83.72) | 56.25 (39.33–71.83) | 100 (89.85–100) | 78.79 (67.49–86.92) |
a
CI, confidence interval; the American tegumentary leishmaniasis group represents test properties calculated for mucosal leishmaniasis patients and cutaneous leishmaniasis patients together.